Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
What This Research Report Covers
This report explains how GHRP-2, GHRP-6, and ipamorelin affect the GH/IGF-1 axis, where the main risks arise, and how medical supervision can reduce those risks.
- GHRPs such as GHRP-2, GHRP-6, and ipamorelin stimulate natural growth hormone and can cause insulin resistance, elevated IGF-1, and hormonal shifts.1
- Metabolic risks are significant, because GH opposes insulin and can raise fasting glucose and insulin resistance within days of starting therapy.1
- Cancer concerns relate to IGF-1 elevation that may support growth of existing or occult malignancies through anti-apoptotic and angiogenic pathways.
- Unregulated online products carry sourcing risks, including mislabeling and contamination with endotoxins, heavy metals, or residual synthesis solvents.
- Medically supervised care at Mirror Plastic Surgery uses baseline testing, vetted sourcing, and structured monitoring to manage these risks.
- Contraindication screening and ongoing lab monitoring are essential parts of any responsible GHRP protocol.
Background: How The GH/IGF-1 Pathway Drives Risk
Growth hormone releasing peptides activate the ghrelin receptor (GHS-R1a) on pituitary cells and trigger pulsatile growth hormone release. GH then signals the liver to produce insulin-like growth factor-1 (IGF-1), which mediates roughly 75% of GH’s growth-promoting effects through endocrine, paracrine, and autocrine signaling (Le Roith et al., 2001).
This pathway creates two core risk mechanisms:
- Insulin resistance: GH directly antagonizes insulin signaling in muscle and liver tissue. IGF-1 promotes insulin sensitivity, yet strong GH-axis stimulation at supraphysiological levels shifts the balance toward impaired glucose handling. A 2026 review in Frontiers in Endocrinology identifies dysglycemia and insulin resistance as class-effect concerns and recommends fasting glucose or HbA1c monitoring for any GHRP protocol.
- Tumor promotion potential: IGF-1 is a potent mitogen that activates PI3K/AKT and MAPK pathways, promoting cell survival and proliferation while inhibiting apoptosis. A UK Biobank analysis of approximately 395,000 participants linked higher circulating IGF-1 to increased colorectal, breast, and prostate cancer risk, with about 9–15% higher risk per standard deviation increase in IGF-1.
Physiologic pulsatile GH release differs from chronic elevation. GHRPs stimulate endogenous pulses that preserve feedback regulation. Supraphysiological sustained elevation from excessive dosing or prolonged use is where pathologic effects emerge. Exogenous HGH produces tonic, non-pulsatile receptor exposure, while GHRPs like ipamorelin produce bursts that better preserve the endogenous rhythm.
Primary Health Risks And Side Effects By Category
Metabolic Risks: Insulin Resistance And Glucose Dysregulation
Growth hormone acts as a counter-regulatory hormone that opposes insulin action, promotes hepatic glucose production, and reduces peripheral glucose uptake. A 2019 Diabetes Care study in poorly controlled type 2 diabetes showed that GH secretagogue use increased fasting glucose by an average of 34 mg/dL within 72 hours of the first dose.
Research using GHRP-6 with the GH receptor blocked by pegvisomant demonstrated additional insulin resistance mechanisms beyond GH itself. Serum insulin rose from 10.3 to 81.3 mU/L and glucose from 4.2 to 6.0 mmol/L. These changes indicate rapid, tissue-specific insulin resistance in liver and muscle.
Cancer Risk: IGF-1 And Mitogenic Signaling
GHRP-induced IGF-1 elevation raises concern because IGF-1 can support growth of existing or occult malignancies. IGF-1 activates anti-apoptotic pathways that allow damaged cells to survive and upregulates VEGF, which promotes angiogenesis and supplies tumors with nutrients and oxygen.
Clinical evidence from acromegaly, a state of chronic GH/IGF-1 excess, shows a standardized incidence ratio of 1.95 for colorectal and anal cancers. In contrast, individuals with Laron syndrome, who have GH receptor deficiency and near-zero IGF-1, show virtually no cancer incidence despite obesity and metabolic complications. This contrast provides strong human evidence that IGF-1 plays a causal role in cancer development.
Hormonal Imbalances: Prolactin, Cortisol, And Acromegaly-Like Effects
Different GHRPs affect other hormonal axes in distinct ways.
- GHRP-6 elevates cortisol and prolactin in a dose-dependent manner, more than GHRP-2 and significantly more than ipamorelin. Elevated prolactin can reduce libido, alter mood, and contribute to fluid retention. Chronically elevated cortisol undermines recovery and promotes fat storage.
- GHRP-2 elevates ACTH and cortisol to a degree comparable to a human corticotropin-releasing hormone challenge, with prolactin elevation below TRH-induced levels.
- Ipamorelin is more selective and shows minimal to no cortisol or prolactin elevation at standard doses, which makes it preferable when hormonal interference must be limited.
Other Documented Side Effects
Several additional side effects relate to elevated GH and IGF-1 or to injection technique.
- Fluid retention: GH-driven sodium and water reabsorption causes dose-dependent, reversible edema. GHRP-6 can add 2–4 kg of fluid weight over 4–8 weeks of daily dosing.1
- Carpal tunnel syndrome: Prolonged elevated IGF-1 can progressively compress the median nerve and may require intervention.
- Injection-site reactions: Redness, bruising, and local irritation occur in 10–20% of administrations, and technique plus needle gauge strongly influence this rate.
- Appetite stimulation: GHRP-6 often produces intense hunger within 20–30 minutes of injection through ghrelin receptor activation, which is inseparable from its mechanism.
Comparative Risk Profile: GHRP-2 Vs. GHRP-6 Vs. Ipamorelin
Note: Sermorelin, a GHRH analog rather than a GHRP, is sometimes discussed alongside these peptides. It acts through a different receptor pathway and has a distinct risk profile, including prior FDA approval (discontinued 2008 for commercial reasons).
Beyond these inherent biological risks, product reliability becomes the next major concern. That concern centers on the quality of the unregulated market.
The Unregulated Market: Documented Quality Failures
The most immediate real-world risk with GHRPs often comes from the supply chain rather than the molecule itself. Independent testing by Finnrick Analytics, covering more than 6,600 samples from over 200 vendors, found that roughly 30% of peptide products were mislabeled, under- or overdosed, or contaminated with toxins or bacteria.
Documented contaminants in peptide products include:
- Bacterial endotoxins that can trigger fever, hypotension, and systemic inflammatory responses at levels as low as 5 EU/kg.
- Heavy metals such as lead, cadmium, and mercury from low-grade reagents, which can cause renal and neurological symptoms that persist long after the peptide clears.
- Residual trifluoroacetic acid (TFA) from synthesis, which can cause injection-site pain, tissue necrosis, and systemic acidosis.
- Truncated peptide fragments and synthesis byproducts with unknown biological activity.
The FDA has issued warning letters to online peptide sellers promoting unapproved products labeled “for research use only,” noting that injectable products bypass key bodily defenses against microorganisms and toxins. A 2023 FDA safety alert documented at least 13 adverse events, including hospitalizations, among individuals who self-administered peptides purchased online without a prescription.
Contraindications: Situations Where GHRPs Should Be Avoided
Clinical literature identifies several absolute contraindications for GHRP use.
- Active malignancy or history of cancer: GH and IGF-1 are mitogenic, and standard oncology protocols require a minimum five-year cancer-free period before any GH secretagogue is considered, and then only with oncologist clearance.
- Diabetes or prediabetes: GH’s counter-regulatory effect on insulin can precipitate hyperglycemic crisis in uncontrolled diabetes, particularly when HbA1c exceeds 8.5%.
- Active diabetic retinopathy: IGF-1 stimulates VEGF expression and neovascularization, which can accelerate retinal hemorrhage.
- Pregnancy and breastfeeding: No safety data exist, and the FDA classifies most GH secretagogues as Category C.
- Pituitary tumors or acromegaly: Direct stimulation of tumor tissue can trigger rapid growth.
- Children and adolescents with open growth plates.
Laboratory Monitoring: Core Elements Of A Safe Protocol
Safe GHRP therapy relies on objective data rather than symptoms alone. Recommended monitoring includes the following markers and timelines.
| Marker | Baseline | Follow-Up | Target |
|---|---|---|---|
| IGF-1 | Yes | 4–6 weeks, then every 8 weeks | Upper-normal range for age, such as 200–300 ng/mL for ages 40–49 |
| Fasting glucose | Yes | Every 8 weeks | No significant increase from baseline |
| HbA1c | Yes | Every 8–12 weeks | Within normal range |
| Fasting insulin (HOMA-IR) | Yes | Every 8 weeks | Below 2.5 |
| Prolactin | Yes (GHRP-2/GHRP-6) | 8 weeks | Within normal range |
| Cortisol | Yes (GHRP-2/GHRP-6) | 8 weeks | Within normal range |
| Thyroid (TSH, fT4) | Yes | 12 weeks | Within normal range |
| Liver function | Yes | 12 weeks | Within normal range |
How Medically Supervised Care Mitigates These Risks
Structured medical oversight changes the risk profile of GHRPs by addressing biological and sourcing risks at each step. Mirror Plastic Surgery’s concierge peptide therapy program, led by Dr. Akash Chandawarkar, links every part of the process to the risk categories described above.
- Comprehensive baseline evaluation: Every protocol starts with a 30–60 minute consultation that reviews medical history, current medications, and health goals. In-depth lab panels covering thyroid, liver, kidney, glucose, IGF-1, and hormone markers identify contraindications such as diabetes, cancer history, or pituitary disease before any peptide is prescribed.
- Quality-assured sourcing: Peptides come from vetted providers who undergo rigorous batch testing for purity, accurate dosing, and sterility. This approach directly addresses the contamination crisis documented earlier in unregulated products.
- Ongoing monitoring: Follow-up labs at 4–6 weeks and then every three months track IGF-1, fasting glucose, HbA1c, prolactin, cortisol, and liver function. This schedule allows clinicians to catch early signs of insulin resistance or hormonal imbalance before they become clinically significant.
- Personalized protocols: Dr. Akash designs each protocol around the client’s specific labs and physiology. He selects the appropriate peptide, such as favoring ipamorelin over GHRP-6 when hormonal interference is a concern, and adjusts dosing based on objective data over time.
Frequently Asked Questions
Are Growth Hormone Releasing Peptides Safe?
GHRPs carry documented risks that include insulin resistance, elevated IGF-1 with tumor-promotion potential, and hormonal imbalances. Under medical supervision with baseline labs, ongoing monitoring, and quality-assured sourcing, many of these risks can be managed. Unsupervised use from unregulated online sources greatly increases the chance of serious problems, because protocol design, sourcing quality, and lack of oversight often matter more than the peptide choice itself.
What Are The Dangers Of Taking Peptides?
The main dangers fall into biological risks and sourcing risks. Biological risks include insulin resistance and elevated IGF-1, which carries theoretical tumor-promotion potential. Hormonal imbalances, especially elevated cortisol and prolactin with GHRP-2 and GHRP-6, can also occur. Fluid retention and carpal tunnel-like symptoms may appear with prolonged use.
Sourcing risks are equally serious. Independent testing shows that a substantial proportion of unregulated peptide products fail quality checks and may contain bacterial endotoxins, heavy metals, residual synthesis solvents, or incorrect peptide content. A contaminated injectable product can cause local or systemic infection, sepsis, or sustained inflammatory responses that outlast the peptide by weeks.
How Long Can You Stay On HGH Peptides?
Most protocols run 8–12 weeks on, followed by 4–8 weeks off, to prevent receptor desensitization and allow hormone levels to normalize. Continuous year-round use increases the risks of insulin resistance, receptor downregulation, and HPA axis dysregulation. With GHRP-2, receptor desensitization often appears between weeks 8–12, reducing GH pulse amplitude even at the same dose.
Duration should be guided by lab monitoring and physician assessment rather than a fixed schedule. The off-cycle period also gives clinicians a chance to confirm that natural GH pulsatility remains intact.
Can GHRPs Cause Cancer?
GHRPs themselves are not mutagenic, so they do not initiate cancer. The concern centers on elevated IGF-1, which may promote growth of existing or occult malignancies by activating anti-apoptotic pathways and stimulating angiogenesis. As discussed in the cancer risk section, epidemiological data links higher circulating IGF-1 to modestly increased risk of several cancers.
Anyone with active cancer or a history of cancer should avoid GHRPs entirely. For individuals without a cancer history, keeping IGF-1 within the age-adjusted reference range through regular monitoring is the key mitigation strategy.
What Is The Difference Between GHRP-2 And Ipamorelin?
GHRP-2 and ipamorelin both activate the GHS-R1a receptor to stimulate pulsatile GH release, yet their selectivity profiles differ. GHRP-2 is more potent for GH release and elevates cortisol and ACTH to a degree comparable to a corticotropin-releasing hormone challenge. It also elevates prolactin in many users at standard doses, which can suppress gonadotropin signaling and contribute to libido suppression and secondary hypogonadism symptoms.
Ipamorelin has a more selective profile, described earlier in the hormonal imbalance section, which makes it preferable when hormonal side effects are a concern. From a regulatory standpoint, both GHRP-2 and ipamorelin carry FDA Category 2 safety risk listings for compounding because of immunogenicity concerns and limited long-term human safety data.
Conclusion
Growth hormone releasing peptides can support body composition, recovery, and anti-aging goals, yet they remain powerful hormonal tools rather than benign supplements.1 Evidence shows that GHRP-2, GHRP-6, and ipamorelin carry real risks of insulin resistance, elevated IGF-1 with tumor-promotion potential, hormonal imbalances, and serious dangers from unregulated sourcing. These risks are manageable, but only under specific conditions: proper medical supervision, comprehensive baseline testing, quality-assured peptides, and ongoing laboratory monitoring.
Mirror Plastic Surgery provides this level of structured care. Dr. Akash Chandawarkar’s concierge approach prioritizes safety, then function, then aesthetics, so every peptide protocol aligns with your physiology and remains under the guidance of a board-certified physician.
Contact our team to find out whether medically supervised GHRP therapy fits your health profile.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Results vary. Peptide therapies are not FDA-regulated; consult a qualified physician.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
